Combination therapy, utilizing Aromatase Inhibitors (AIs) alongside targeted agents, has emerged as one of the promising approaches in the treatment of hormone-sensitive breast cancer in postmenopausal women. This is because endocrine or hormonal therapy was found effective in hormone-sensitive breast cancer for a considerable period of time.
